GlassScriptPhysician profile
Joseph J Vanvaler
NPI 1689629180
$17,846.90
in general payments reported to CMS, 2019-2025
47 companies · $1,035 in 2025
The $1,035 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,532 · 2020: $1,058 · 2021: $1,813 · 2022: $9,584 · 2023: $1,762 · 2024: $1,063 · 2025: $1,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,860.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $7,823.29 | 2022 | |
| Acadia Pharmaceuticals INC | $996.77 | 2019-2025 | Nuplazid |
| Livanova USA, INC. | $886.50 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Genzyme Corporation | $804.14 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $671.19 | 2019-2023 | Ingrezza |
| Abbvie INC. | $596.53 | 2021-2025 | Ubrelvy, Qulipta |
| Harmony Biosciences LLC | $590.53 | 2020-2025 | Wakix |
| Emd Serono, INC. | $537.49 | 2019-2023 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $470.41 | 2019-2025 | Ultomiris, Soliris |
| Eisai INC. | $317.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $307.60 | 2019-2022 | |
| Ucb, INC. | $298.66 | 2019-2025 | Zilbrysq |
| Biohaven Pharmaceuticals, INC. | $290.87 | 2021 | |
| Sunovion Pharmaceuticals INC. | $276.66 | 2019-2021 | |
| Lilly USA, LLC | $266.38 | 2019-2022 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $233.48 | 2019-2021 | |
| Lundbeck LLC | $222.30 | 2024 | Vyepti |
| Allergan, INC. | $198.15 | 2019-2020 | |
| Tg Therapeutics, INC. | $197.93 | 2023 | |
| Mdd US Operations, LLC | $191.71 | 2019-2023 | Apokyn |
| Amgen INC. | $181.62 | 2019-2025 | |
| Genentech USA, INC. | $167.51 | 2019-2022 | |
| Neurelis, INC. | $137.28 | 2022-2025 | Valtoco |
| Kyowa Kirin, INC. | $117.68 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $117.58 | 2024 | Lumryz |
| Axsome Therapeutics, INC. | $115.20 | 2024 | Auvelity |
| Pfizer INC. | $108.47 | 2024 | |
| Horizon Therapeutics Plc | $95.25 | 2022 | |
| Novo Nordisk INC | $82.75 | 2019-2025 | Wegovy |
| Jazz Pharmaceuticals INC. | $81.33 | 2021-2024 | |
| Amarin Pharma, INC. | $59.46 | 2019 | |
| Exact Sciences Corporation | $51.52 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $42.66 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $38.70 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $38.64 | 2021 | |
| Amneal Pharmaceuticals LLC | $37.05 | 2021-2022 | |
| Boston Scientific Corporation | $27.06 | 2025 | Watchman Flx |
| Biogen, INC. | $24.02 | 2021 | |
| Sk Life Science, INC. | $21.22 | 2022 | |
| Corium, LLC | $20.83 | 2022 | |
| Ge Healthcare | $20.44 | 2019 | |
| Medtronic, INC. | $18.55 | 2024 | Intellis Adaptivestim |
| Mallinckrodt Hospital Products INC. | $14.37 | 2021 | |
| Inspire Medical Systems, INC. | $13.67 | 2023 | Inspire |
| Upsher-Smith Laboratories LLC | $12.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.79 | 2021 | |
| Adamas Pharmaceuticals, INC. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vanvaler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.